Ausio Pharmaceuticals

Ausio Pharmaceuticals, LLC. is a clinical-stage biotechnology development company dedicated to advancing safe and effective drugs. Ausio's lead product is AUS-131, a first-in-class non-steroidal, non-hormonal estrogen receptor beta (ERβ) agonist. Ausio has successfully completed two Phase 1 trials, a Phase 2a study for menopausal symptoms, and a Phase 2a study for benign prostatic hyperplasia (BPH). Currently, Ausio is conducting clinical research in patients with Alzheimer's disease and in women with triple-negative breast cancer.